Cardiff Oncology, Inc.
CRDF
$1.79
-$0.03-1.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 593.00K | 501.00K | 546.00K | 588.00K | 684.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 593.00K | 501.00K | 546.00K | 588.00K | 684.00K |
| Cost of Revenue | 2.38M | 4.77M | 6.22M | 4.13M | 1.66M |
| Gross Profit | -1.78M | -4.27M | -5.67M | -3.54M | -977.00K |
| SG&A Expenses | 14.22M | 14.24M | 13.47M | 13.37M | 12.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.55M | 54.21M | 54.88M | 52.69M | 49.34M |
| Operating Income | -48.96M | -53.71M | -54.33M | -52.10M | -48.65M |
| Income Before Tax | -45.85M | -50.42M | -51.02M | -48.85M | -45.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.85 | -50.42 | -51.02 | -48.85 | -45.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.85M | -50.42M | -51.02M | -48.85M | -45.43M |
| EBIT | -48.96M | -53.71M | -54.33M | -52.10M | -48.65M |
| EBITDA | -48.60M | -53.33M | -53.95M | -51.71M | -48.25M |
| EPS Basic | -0.69 | -0.80 | -0.88 | -0.94 | -0.96 |
| Normalized Basic EPS | -0.43 | -0.50 | -0.55 | -0.58 | -0.60 |
| EPS Diluted | -0.69 | -0.80 | -0.88 | -0.94 | -0.96 |
| Normalized Diluted EPS | -0.43 | -0.50 | -0.55 | -0.58 | -0.60 |
| Average Basic Shares Outstanding | 267.36M | 254.15M | 234.13M | 212.43M | 190.59M |
| Average Diluted Shares Outstanding | 267.36M | 254.15M | 234.13M | 212.43M | 190.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |